GlassScriptPhysician profile
Manoj Kantu
NPI 1679617971
$6,202.64
in general payments reported to CMS, 2019-2025
18 companies · $906 in 2025
The $906 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $660 · 2021: $1,014 · 2022: $1,275 · 2023: $647 · 2024: $634 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,224.65 | 2019-2022 | |
| Optinose US, INC. | $1,065.66 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,021.37 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $614.57 | 2020-2025 | Nucala |
| Acclarent, INC | $494.98 | 2019-2022 | |
| Intersect Ent, INC. | $459.57 | 2021-2022 | |
| Genzyme Corporation | $389.72 | 2019-2025 | |
| Aerin Medical INC. | $381.64 | 2022-2023 | |
| Medtronic, INC. | $229.52 | 2021-2025 | Novapak, Propel, Stealthstation S8 Platform |
| Pfizer INC. | $86.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $51.56 | 2023 | |
| Hikma Pharmaceuticals USA | $47.85 | 2023 | Ryaltris |
| Integra Lifesciences Corporation | $34.92 | 2024 | Acclarent Aera |
| Neurent Medical Limited | $24.55 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Ars Pharmaceuticals Operations, INC. | $21.03 | 2025 | Neffy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.78 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.65 | 2025 | Tezspire |
| Cumberland Pharmaceuticals, INC. | $15.44 | 2024 | Caldolor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoj Kantu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.